Head-to-head comparison
Invyncible vs MedLeanRx
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Invyncible is a Florida telehealth platform pricing every GLP-1 dose program in the open, with all six of its compounding pharmacies named and patient-selectable.
From $149/mo (lowest dose rung) sema · From $180/mo (lowest dose rung) tirz · Verified August 2026
Marked down on: The entry price buys the smallest vial: the same plain semaglutide program runs $262.50 at 5 mg and $350 at 10 mg, which the FAQ confirms
Desk Score
MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX.
$149/mo (promo rate) sema · From $269/mo (lowest dose rung) tirz · Verified July 2026
Marked down on: Texas only — not available in the other 49 states
Invyncible takes this head-to-head with the higher Desk Score, 73/100 (C) against 69/100 (C) for MedLeanRx. MedLeanRx still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Invyncible
73/100
C
MedLeanRx
69/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Invyncible | MedLeanRx |
|---|---|---|
| Semaglutide | From $149/molowest dose rung$149/mo (0.45 mg dose, compounded with glycine + B12) | $149/mopromo rate$149/mo (starting dose, promotional rate, compounded) |
| Tirzepatide | From $180/molowest dose rung$180/mo (2.5 mg weekly, 4-week program, compounded) | From $269/molowest dose rung$269/mo (starting dose, compounded) |
| Coverage | 46 states plus DC | 1 state |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | An open price list and a named, patient-selectable compounding pharmacy rather than an unnamed network. | Texas-only compounded semaglutide at $149/mo with a brand Wegovy and Zepbound pathway. |
| Desk Score | 73/100C | 69/100C |
The verdict
Desk pick — InvyncibleInvyncible takes this head-to-head with the higher Desk Score, 73/100 (C) against 69/100 (C) for MedLeanRx. MedLeanRx still holds its ground where its strengths line up with yours.
Choose Invyncible if…
An open price list and a named, patient-selectable compounding pharmacy rather than an unnamed network.
From $149/mo (lowest dose rung) sema · From $180/mo (lowest dose rung) tirz · 46 states plus DC
Choose MedLeanRx if…
Texas-only compounded semaglutide at $149/mo with a brand Wegovy and Zepbound pathway.
$149/mo (promo rate) sema · From $269/mo (lowest dose rung) tirz · 1 state
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Invyncible · MedLeanRx.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Invyncible
- CoreAge Rx vs MedLeanRx
- Invyncible vs Ondra Health
- MedLeanRx vs Vaylen
- Invyncible vs Vaylen
- MedLeanRx vs PCOS Sisters
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.